Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | FADS1 | O60427 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.35 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801676 | 0.89 | FADS1 (0.46) | GSK3AGSK3BFADS1EGFRRIPK2 | |
| SCHEMBL802350 | 0.89 | EGFR (0.41) | FADS1EGFREPHA4CYP1A2CYP3A4 | |
| SCHEMBL10267479 | 0.88 | ACP1 (0.40) | GSK3AGSK3BFADS1EGFRRIPK2 | |
| SCHEMBL802269 | 0.83 | GSK3A (0.44) | GSK3AGSK3BFADS1EGFRRIPK2 | |
| SCHEMBL801639 | 0.83 | GSK3A (0.50) | GSK3AGSK3BFADS1EGFRRIPK2 | |
| SCHEMBL802675 | 0.79 | GSK3A (0.51) | GSK3AGSK3BFADS1EGFRRIPK2 | |
| SCHEMBL801665 | 0.79 | FADS1 (0.51) | GSK3AGSK3BFADS1RIPK2ITK | |
| SCHEMBL802250 | 0.78 | FADS1 (0.45) | GSK3AGSK3BFADS1EGFRRIPK2 | |
| SCHEMBL801681 | 0.78 | FADS1 (0.43) | GSK3AGSK3BFADS1EGFREPHA4 | |
| SCHEMBL805597 | 0.77 | ACP1 (0.39) | FADS1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | GSK3A 2/4885GSK3B 1/4885FADS1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.